Urcosimod (OK-101)

About OKYO Pharma

OKYO Pharma is dedicated to developing innovative treatments for debilitating ocular conditions, specifically Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED). The company's lead asset, Urcosimod, leverages a proprietary Membrane Anchored Peptide (MAP) technology to enhance drug residence time and potency at the ocular surface. OKYO has achieved a key milestone by receiving FDA IND clearance for Urcosimod in NCP, positioning it as a first-mover in a space with no approved therapies.

About OKYO Pharma

OKYO Pharma is dedicated to developing innovative treatments for debilitating ocular conditions, specifically Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED). The company's lead asset, Urcosimod, leverages a proprietary Membrane Anchored Peptide (MAP) technology to enhance drug residence time and potency at the ocular surface. OKYO has achieved a key milestone by receiving FDA IND clearance for Urcosimod in NCP, positioning it as a first-mover in a space with no approved therapies.

Therapeutic Areas